Tobramycin dosing in cystic fibrosis

Alan Smyth*, Daan Touw, Kelvin H-V Tan, Carol Bertenshaw, David Stableforth

*Corresponding author for this work

Research output: Contribution to journalLetterAcademicpeer-review

6 Citations (Scopus)
Original languageEnglish
Pages (from-to)1767-1768
Number of pages2
JournalThe Lancet
Volume365
Issue number9473
DOIs
Publication statusPublished - May-2005

Keywords

  • aminoglycoside antibiotic agent
  • ceftazidime
  • tobramycin
  • acute kidney failure
  • antibiotic resistance
  • clinical trial
  • cystic fibrosis
  • drug dose regimen
  • human
  • letter
  • minimum inhibitory concentration
  • nephrotoxicity
  • priority journal
  • Pseudomonas aeruginosa
  • sputum culture

Cite this